Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 90 |
| Active Pipeline (Recruiting Now) | 63 (35) |
| Completed vs Stopped Early | 12 / 15 (16.7%) |
| Median Closed Actual Enrollment | 22 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Moffitt Cancer Center | Tampa, FL | 87 |
| Ohio State University Comprehensive Cancer Center | Columbus, OH | 4 |
| Roswell Park Comprehensive Cancer Center | Buffalo, NY | 3 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06701812 | Digoxin Medulloblastoma Study | Phase II | RECRUITING |
| NCT06745882 | Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC | Phase II | RECRUITING |
| NCT04388839 | Evolutionary Therapy for Rhabdomyosarcoma | Phase II | ACTIVE NOT RECRUITING |
| NCT03610971 | Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors | Phase II | ACTIVE NOT RECRUITING |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Moffitt Cancer Center across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the H. Lee Moffitt Cancer Center and Research Institute Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.